Brain47Brain47Join Brain47
0O2

Sagimet Biosciences Inc.

Healthcare · EUR · F

0O2

Price

€5.956

+7.61%

Cap

€476.11M

Earnings

—

30d Trend

+18.2%

0O2
Loading chart data...
0 days · % change from startPowered by Brain47

BRAIN47 SIGNAL

0
MODERATE
Risk Level85
Quality34
Momentum77
Technical62
Fundamentals50

Raw weighted: 51×Macro 0.99 (−1%)=50

RISK

85/100
90d Volatility
95.1%High
ATR %
7.2%High daily moves
Max Drawdown (1Y)
-55.6%Volatile

QUALITY

34/100
ROE (avg)
-45.8%Negative
Piotroski F-Score
3/9Weak
Accruals
-4.6%Cash earnings

MOMENTUM

77/100
12-1M Momentum
+129.8%Strong uptrend
6-1M Momentum
+17.5%Positive
1M Return
-17.5%Sharp decline
Relative Strength
+1.7% vs sectorIn-line

TECHNICAL

62/100
RSI (14)
53.3Neutral
Price vs SMA200
+8.9%Bullish trend
MACD
-0.10Bearish momentum
Bollinger Band
39%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.310Mixed

FUNDAMENTALS

50/100

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months38
3-12 months ★71
1-5+ years44

3-6 month momentum thesis — strong trend with confirmation

BRAIN47'S ASSESSMENT

I rate Sagimet Biosciences Inc. at 50/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 77/100. I classify this as a speculative position with the strongest thesis on a medium-term horizon.

DETAILED ANALYSIS

3-6 month momentum thesis — strong trend with confirmation. Momentum (77) and Technical (62) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. I classify this as a speculative position — elevated volatility at 95% and smaller market cap define the opportunity.

speculativeScore: 50/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.